SCHEMBL5790195

SCHEMBL5790195

CN1CCN(c2cccc(CC(N)=O)c2)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AGXT P21549 1/20 0.61
ITGB3 P05106 2/20 0.55
ITGA2B P08514 2/20 0.55
ADRA2C P18825 2/20 0.55
PLOD2 O00469 1/20 0.49
PLOD3 O60568 1/20 0.49
PLOD1 Q02809 1/20 0.49
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
AOC3 Q16853 3/20 0.47
HTR6 P50406 2/20 0.47
CCNA2 P20248 2/20 0.47
CDK2 P24941 2/20 0.47
CCNA1 P78396 2/20 0.47
HTR1A P08908 2/20 0.46
HTR2A P28223 2/20 0.46
HTR7 P34969 1/20 0.46
HTR2C P28335 2/20 0.45
ADRA2A P08913 1/20 0.45
ADRA2B P18089 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20425007 0.87 ITGB3 (0.64) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL20392367 0.86 ITGB3 (0.56) AGXTITGB3ITGA2BAOC3HTR6
SCHEMBL28030655 0.86 AGXT (0.58) AGXTITGB3ITGA2BNPC1RAB9A
SCHEMBL17890851 0.85 AGXT (0.57) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL28739636 0.85 ITGB3 (0.62) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL29639816 0.85 AGXT (0.56) AGXTITGB3ITGA2BNPC1RAB9A
SCHEMBL5790197 0.83 AGXT (0.61) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL29589898 0.83 AGXT (0.58) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL15710135 0.83 AGXT (0.58) AGXTITGB3ITGA2BADRA2CPLOD2
SCHEMBL5177552 0.82 AGXT (0.61) AGXTITGB3ITGA2BPLOD2PLOD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1423121-B1 CYSTEINE PROTEASE INHIBITORS WITH 2-CYANO-4-AMINO-PYRIMIDINE STRUCTURE AND CATHEPSIN K INHIBITORY ACTIVITY FOR THE TREATMENT OF INFLAMMATIONS AND OTHER DISEASES NOVARTIS AG (CH) 2006-11-15 EP disclosed
US-7112589-B2 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases NOVARTIS AG (CH) 2006-09-26 US disclosed
US-20060074092-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases ALTMANN EVA 2006-04-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060074092-A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin K inhibitory activity for the treatment of inflammations and other diseases CTSK, CTSS, CTSZ AGXT 1197/4885ITGB3 4109/4885ITGA2B 3389/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.